Erbb2 Gene Mutation is found in 2% of individuals with Non-Small Cell Lung Cancer. The mutation is generally a small insertion in the Erbb2 gene, and causes the continuous activation of a mutant kinase called HER2. Non-Small Cell Lung Cancers typically do not respond to chemotherapy or radiation therapy, and few patients diagnosed with the cancer are cured. Erbb2 Gene Mutation is detected through a specific genotypic test, which is being added to the systematic testing of patients with Non-Small Cell Lung Cancer. Drugs, such as trastuzumab, that target HER2 overexpression in other forms of gastric and breast cancer are currently being tested on lung cancers with Erbb2 Gene Mutations, and the reaction to the medication in clinical trials seems promising.
Erbb2 Gene Mutation Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Erbb2 Gene Mutation below!
For more information on how to use Laverne, please read the How to Guide.
We have 1212 products for the study of Erbb2 Gene Mutation that can be applied to Chromatin Immunoprecipitation, Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits.